Ever Supreme is the contracted cell preparation site of China Medical University Hospital under the RGSCTT, and the hospital applied to Taiwan FDA for “Allogenic immune cells (CIK) treating hematological malignancies after unsuccessful conventional therapy”, and received approval by Taiwan FDA on Dec 7 2020 as a qualified GTP cell preparation site.
Permitted items in China Medical University Hospital the development plan is as followed:
(1)Excution of item: autologous immune cell therapy (CIK).
(2)Indications: Hematological malignancies after ineffective conventional treatment; cancer types: Hodgkin’s lymphoma, B-cell non-Hodgkin’s lymphoma, acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, chronic lymphoid leukemia, multiple myeloma.
(3)Cell preparation site: Cell Preparation Sites of Ever Supreme Bio Technology Co., LTD.
(4)Validity: Dec 7 2020 to May 14, 2022.